ERBB2 and lung carcinoma: On the other hand, the prevalence of ErbB family gene fusions in our lung cancer cohort was non-negligible reaching 0.23%, with the majority of these patients carrying EGFR (0.11%) and ERBB2 (0.07%) fusions.